Search results
Apr 30, 2024 · LysVPp1’s lytic activity was assessed by measuring absorbance reduction against various pathogenic Vibrio strains. Phage CH20 exhibited a limited host range, affecting only Vibrio alginolyticus GV09, a highly pathogenic strain.
May 1, 2024 · Examples of unique features of the V. cholerae genome include the bacteriophage CTXΦ, which is a lysogenic bacteriophage that infects bacteria and inserts genetic material into the genome, and the Vibrio pathogenicity island, which encodes the toxin that allows intestinal colonization. [12]
- Jafet A. Ojeda Rodriguez, Chadi I. Kahwaji
- 2022/09/01
- USAF, Universtity of California, Irvine
People also ask
Are Vibrio cholerae toxic?
What is the antigenic structure of V cholerae?
What are the key facts about V cholerae infection?
May 20, 2024 · This report summarizes illnesses reported to the Cholera and Other Vibrio Illness Surveillance System (COVIS) in 2019. Data include geographic distribution, demographic and clinical characteristics, routes of transmission, and more.
May 13, 2024 · Notably, the comparison of treatments showed that phage CH20 was notably more effective at reducing Vibrio counts, compared to endolysin. The host range of CH20 was limited, in contrast to other Vibrio phages that exhibit a broad range of lytic activity.
May 9, 2024 · The lytic phage ICP1 that co-circulates with V. cholerae encodes the BREX inhibitor OrbA, but how OrbA inhibits BREX is unclear. Here, we determine that OrbA inhibits BREX using a unique mechanism from known BREX inhibitors by directly binding to the BREX component BrxC.
May 14, 2024 · The Cholera and Other Vibrio Illness Surveillance (COVIS) system is used for reporting U.S. cases of Vibrio infection (cholera and vibriosis). Information in COVIS helps CDC track infections and determine patient, food, and environmental risk factors.
Apr 30, 2024 · Our results demonstrated the significant lytic effect of endolysin LysVPp1 on strains of Vibrio alginolyticus, Vibrio parahaemolyticus, and Vibrio splendidus.
